Israel - Tiếng Do Thái - Ministry of Health

rafa laboratories ltd - fluconazole - קפסולות - fluconazole 50 mg - fluconazole - fluconazole - cryptococcosis. systemic candidiasis. mucosal candidiasis. vaginal candidiasis.

Israel - Tiếng Do Thái - Ministry of Health

rafa laboratories ltd - fluconazole - קפסולות - fluconazole 100 mg - fluconazole - fluconazole - cryptococcosis. systemic candidiasis. mucosal candidiasis. vaginal candidiasis.

Israel - Tiếng Do Thái - Ministry of Health

rafa laboratories ltd - fluconazole - קפסולות - fluconazole 200 mg - fluconazole - fluconazole - cryptococcosis. systemic candidiasis. mucosal candidiasis. vaginal candidiasis.

Israel - Tiếng Do Thái - Ministry of Health

salomon,levin & elstein ltd - fluconazole 100 mg - capsules - fluconazole - cryptococcosis. - systemic candidiasis. - mucosal candidiasis. - vaginal candidiasis. - dermatomycosis.

Israel - Tiếng Do Thái - Ministry of Health

abic marketing ltd, israel - fluconazole - קפסולות - fluconazole 150 mg - fluconazole - fluconazole - cryptococcosis. - systemic candidiasis. - mucosal candidiasis. - vaginal candidiasis. - dermatomycosis.

Israel - Tiếng Do Thái - Ministry of Health

j-c health care ltd - itraconazole 100 mg - capsules - itraconazole - blastomycosis (pulmonary and extrapulmonary). histoplasmosis . onychomycosis caused by dermatophytes and/or yeasts. dermatomycoses. vulvovaginal candidosis. oral candidosis. prevention of fungal infection during neutropenia in immunodeficient patients.

Israel - Tiếng Do Thái - Ministry of Health

rafa laboratories ltd - itraconazole - קפסולות - itraconazole 100 mg - itraconazole - itraconazole - blastomycosis (pulmonary and extrapulmonary). histoplasmosis. onchomycosis caused by dermatophytes and/or yeast. dermatomycoses. vulvovaginal candidosis. oral candidosis. prevention of fungal infection during neutropenia in immunodeficient patients.

Israel - Tiếng Do Thái - Ministry of Health

bayer israel ltd - regorafenib - טבליות מצופות פילם - regorafenib 40 mg - regorafenib - regorafenib - stivarga is indicated for the treatment of patients with metastatic colorectal cancer (crc) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf therapy, and if kras wild-type, an anti-egfr therapy.for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumors (gist) who have been previously treated with imatinib mesylate and sunitinib malate

Israel - Tiếng Do Thái - Ministry of Health

medison pharma ltd - triptorelin as acetate - אבקה וממס להכנת תרחיף להזרקה - triptorelin as acetate 3.75 mg/vial - triptorelin - triptorelin - prostate cancer: treatment of prostate cancer with metastases. patients who have not previously received hormone therapy show a more marked response to the treatment and respond more frequently if the patient has not previously receieved another hormone treatment. precocious puberty: (before 8 years in girls and 10 years in boys). genital and extragenital endometriosis (stage i to stage iv): treatment should not be administered for more than 6 months. it is not recomended to start a second treatment course with triptorelin or another gnrh analogue. treatment of uterine fibromyomas prior to surgery: associated with anaemia ( haemoglobin less than, or equal to 8 g/dl). when a reduction in the size of the fibromyoma is necessary to facilitate or modify the surgical technique: endoscopic surgery, transvaginal surgery. the treatment duration is restricted to 3 months. female infertility: supplementary treatment in combination with gonadotrophins (hmg, fsh, hcg) to induce ovulation with a view to in vitro fertilisa

Israel - Tiếng Do Thái - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.